Gland Pharma shares up nearly 15% after Q4 FY2026 results
NewsBytes | May 18, 2026 5:40 PM CST
PAT nearly doubles to ₹366.67cr
The company's profit after tax almost doubled year over year to ₹366.67 crore this quarter, while revenue grew 22% thanks to more production capacity and fresh product launches.
EBITDA rose by 48%, with margins improving from 24% to 29%, boosted by better cost control and renegotiated contracts.
Gland Pharma's board is recommending a ₹20 per share dividend for FY 2026 (pending shareholder approval).
Executive Chairman Srinivas Sadu credited the gains to growth in its CDMO segment, new products, and smart cost moves, adding he is confident about keeping up the momentum.
READ NEXT
-
Bhopal: Accused in assault of Muslim man not linked to Hindutva groups, claim police
-
Bhopal: Accused in assault of Muslim man not linked to Hindutva groups, claim police
-
ED searches premises linked to AAP leader Deepak Singla in money laundering case
-
For children: Pajapati is inconsolable when her sister Maya dies after giving birth to Siddhartha
-
Indian markets tumble as West Asia tensions and oil price spike rattle investors
